The treatments available for smoldering multiple myeloma (MM) are limited, with typical recommendations of observation or enrollment in clinical trials. Here, Ola Landgren, MD, PhD, from the Memorial Sloan Kettering Cancer Center, New York, NY, discusses the Phase II randomized, open-label, multicenter CENTAURUS study of daratumumab monotherapy for high- and intermediate-risk smoldering MM (NCT02316106). Prof. Landgren provides overview of the three study arms, in addition to the two primary endpoints and results. He also discusses plans for a Phase III study and the promise of this treatment. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.